Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abiraterone, added, adding, African, ATM, beta, bevacizumab, biliary, cease, Clostridium, Code, cSCC, Cubicin, Cubist, curable, curative, Department, difficile, Dificid, DOI, EFS, entirety, enzalutamide, Ervebo, Fast, fidaxomicin, force, Forum, harboring, hormonal, HRR, HRRm, induced, Inter, intermediate, IPR, lactamase, letter, mCRPC, median, moved, NaN, NDA, NMPA, Orphan, parallel, phosphate, prequalification, PROfound, QIDP, radiation, radiographic, reconsider, renminbi, reorganization, reprioritization, resistance, routine, scientific, Sivextro, stable, stronger, suppressed, suspension, tedizolid, TNBC, Track, trend, unlawfully, USPTO, vulnerable, withdrawing, Zaire
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 31.1 Exhibit 31.1 Rule 13A-14(A)/15D-14(A) Certification of CEO 3Q19
- 31.2 Exhibit 31.2 Rule 13A-14(A)/15D-14(A) Certification of CFO 3Q19
- 32.1 Exhibit 32.1: Section 1350 Certification of CEO 3Q19
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO 3Q19
- Download Excel data file
- View Excel data file
Related press release
Associated MRK transcripts
MRK similar filings
Filing view
External links